Funds to pursue development of INV-101 and other promising peripheral CB1 blockers to clinical proof-of-concept, as well as to expand the Company’s operations. Board of Inversago strengthened with the appointment of three new directors. MONTREAL (CANADA) – September 8th, 2020 –Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today announced it […]

Proceeds to enable the Company’s continued clinical development of LB-102 for the treatment of schizophrenia New York, NY (Sept 24, 2020) – LB Pharmaceuticals Inc, a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, today announced the closing of a $10.0 million convertible note offering through a private

Phase 1 clinical trial evaluated multiple doses of LB-102 (N-methyl amisulpride) in 64 healthy adults ages 18-55 years LB-102 was safe and well-tolerated and displayed dose linear PK Phase 2 clinical study in schizophrenia patients planned for mid- 2021; retains Mizuho Securities as exclusive financial advisor New York, NY (Sept 14th, 2020) – LB Pharmaceuticals

Nacuity Pharmaceuticals Announces Initiation of SLO-RP (Safety and Efficacy of NPI-001 Tablets versus PLacebO for Treatment of Retinitis Pigmentosa Associated with Usher Syndrome) Phase 1/2 Clinical Trial NPI-001 Being Evaluated for the Treatment of Retinitis Pigmentosa in Patients with Usher Syndrome FORT WORTH, TX, May 18, 2020 – Nacuity Pharmaceuticals, Inc., a clinical stage biotech company focused on the

New York, NY (January 22nd, 2020) – LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1 clinical trial. LB-102 is a novel benzamide designed to be an improved version